The Herpevac Trial for Women (Belshe et al., N Engl J Med 2012) tested a herpes simplex virus type 2 (HSV-2) glycoprotein D subunit vaccine (gD-2/AS04) in 8323 HSV-seronegative women. The outcome was paradoxical: 58% efficacy against HSV-1 genital disease and 35% against HSV-1 infection, but no efficacy against HSV-2 disease or infection, despite the antigen being derived from HSV-2 and the same vaccine having shown 73–74% efficacy against HSV-2 genital disease in women in prior HSV-discordant-couple trials. Follow-up literature through 2026 has established that higher anti-gD-2 binding and neutralizing antibody levels correlate with the HSV-1 protection, has offered a candidate mechanism (HSV-2 glycoproteins gC2 and gE2 shield the virion from gD-2-induced neutralizing antibody, while the HSV-1 counterparts do not), and has reproduced the type-specific pattern in a cotton rat model — yet the field's own assessments state that the lack of protection against HSV-2 remains unexplained, and the observation that breakthrough HSV-2 infections in vaccinees shed virus on more days (29% vs 19% of days, relative risk 1.55) has never been followed up. The open problem is the validated mechanistic explanation of the type-specific efficacy pattern: which immune responses mediate HSV-1 protection and why they fail against HSV-2.

Background

Herpes simplex virus types 1 and 2 (HSV-1, HSV-2) are highly prevalent neurotropic double-stranded DNA viruses that establish lifelong latency in sensory ganglia and periodically reactivate to cause oral or genital lesions; HSV-2 is sexually transmitted and the leading cause of genital ulcer disease worldwide, while HSV-1, classically oral, now causes a large fraction of new genital herpes cases in young women. After primary infection both types alternate between latent and reactivating states, with subclinical reactivation detected as shedding of viral DNA on anogenital swabs by quantitative polymerase chain reaction (PCR); such asymptomatic shedding drives transmission to sexual partners and, in pregnant women, to neonates, where herpes can be devastating.

Genital herpes has no licensed vaccine. The candidate that advanced furthest is a subunit vaccine: 20 µg of recombinant HSV-2 glycoprotein D (gD-2, the viral surface protein that binds cellular entry receptors and is the principal target of neutralizing antibody) adjuvanted with AS04 (3-O-deacylated monophosphoryl lipid A, a Toll-like-receptor-4 agonist, adsorbed onto aluminum salt). In earlier trials this vaccine was tested in HSV-discordant couples (couples in which one partner has genital herpes and the other is uninfected); it showed 73% and 74% efficacy against HSV-2 genital disease in women seronegative for both HSV types, but none in men or HSV-1-seropositive women (Stanberry et al., N Engl J Med 2002).

On that basis, the Herpevac Trial for Women (Belshe et al., N Engl J Med 2012) randomized 8323 women aged 18–30 who were seronegative for both HSV-1 and HSV-2 (antibody-negative by type-specific Western blot) to receive gD-2/AS04 or a hepatitis A control vaccine at months 0, 1, and 6. The primary endpoint was genital herpes disease from either virus type. The result was unexpected: overall efficacy was 20% (95% confidence interval −29 to 50); against HSV-1 genital disease it was 58% (95% CI 12 to 80) and against HSV-1 infection with or without disease 35% (95% CI 13 to 52); against HSV-2 infection efficacy was −8% (95% CI −59 to 26), i.e., none. The trial also ran two substudies that inform the open problem and its background. In an immunogenicity substudy, gD-2 binding antibody measured by enzyme-linked immunosorbent assay (ELISA) at month 7 was lower in vaccinees who subsequently acquired HSV-1 (mean titer 3561) than in those who remained uninfected (6875; P=0.04), whereas no such difference existed for HSV-2 acquisition, and no measure of cellular (T-cell) immunity correlated with protection — a preliminary correlate of protection (an immune measurement that statistically predicts protection) for HSV-1 only. In a viral-shedding substudy, 43 subjects with breakthrough HSV-2 infection (30 vaccine, 13 control) collected daily anogenital swabs for 60 days: vaccine recipients shed HSV-2 DNA on a higher proportion of days (29% vs 19%; relative risk 1.55; 95% CI 1.28 to 1.86), with no difference in the quantity shed on positive days.

The trial's authors posed the puzzle without resolving it: why does an HSV-2-derived antigen protect against HSV-1 but not HSV-2, when the two glycoprotein D molecules share about 89% amino-acid identity and the same vaccine had protected against HSV-2 disease in discordant couples? Hypotheses they raised include differences between the study populations (possible immunologic priming of discordant-couple women by chronic antigen exposure, or selection of relatively resistant women), differences in exposure (HSV-1 genital acquisition often occurs via oral–genital contact, plausibly with a smaller inoculum in a less permissive mucosal environment than for HSV-2), and type-specific neutralization sensitivity. Subsequent laboratory work sharpened the immunologic hypothesis: HSV-2 carries glycoproteins gC2 and gE2 that act as immune-evasion molecules (gC2 binds complement C3b and gE2 binds the Fc portion of IgG), and both have been shown to shield virions from neutralization by gD-2 vaccine antibody, whereas the HSV-1 counterparts gC1/gE1 do not block gD-2-directed neutralization.

Problem Statement

Explain, mechanistically and with supporting evidence, the type-specific outcome pattern of the Herpevac Trial for Women, in which an HSV-2 glycoprotein D subunit vaccine (gD-2/AS04) administered to HSV-1/HSV-2-seronegative women protected against HSV-1 genital disease (58%; 95% CI 12–80) and HSV-1 infection (35%; 95% CI 13–52) but gave no protection against HSV-2 infection (−8%; 95% CI −59 to 26) or disease, despite the antigen being HSV-2-derived and the same vaccine having shown 73–74% efficacy against HSV-2 genital disease in women in HSV-discordant-couple trials. Identify the vaccine-induced immune responses — humoral and cellular, measured by specified assays — that mediate the observed protection against HSV-1, and establish why these responses fail against HSV-2, adjudicating among the candidate explanations raised in the source (population/exposure differences including immunologic priming in discordant couples; route and inoculum differences between HSV-1 and HSV-2 genital acquisition; type-specific neutralization resistance and antibody shielding by HSV-2 gC2/gE2); and determine which vaccine-induced humoral or cellular responses predict HSV-2 acquisition among vaccine recipients — a correlate of risk, distinct from the HSV-1 correlate of protection — specifying, for each candidate response, the comparison between vaccinees who did and did not acquire HSV-2 and any measurement beyond those already reported that would be required to establish the association. Answers must be consistent with the trial's published efficacy, immunogenicity, and shedding data; the shedding data enter only as a consistency constraint, and explaining the elevated HSV-2 shedding observed among vaccine recipients is not required. The translational goal motivating this question — a prophylactic vaccine preventing infection and disease by both HSV types — is background and is not required by the question.

References

  1. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Ashley Morrow RL, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CD; Herpevac Trial for Women. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012;366(1):34-43. doi:10.1056/NEJMoa1103151. https://doi.org/10.1056/NEJMoa1103151
  2. Belshe RB, Heineman TC, Bernstein DI, Bellamy AR, Ewell MG, van der Most R, Deal CD. Correlate of immune protection against HSV-1 genital disease in vaccinated women. J Infect Dis 2014;209(6):828-836. doi:10.1093/infdis/jit651. https://doi.org/10.1093/infdis/jit651
  3. Awasthi S, Belshe RB, Friedman HM. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine. J Infect Dis 2014;210(4):571-575. doi:10.1093/infdis/jiu177. https://doi.org/10.1093/infdis/jiu177
  4. Belshe RB, Blevins TP, Yu Y, Nethington AE, Bellamy A, Bryant C, Morrison LA. Neutralizing antibody kinetics and immune protection against herpes simplex virus 1 genital disease in vaccinated women. J Infect Dis 2023;227(4):522-527. doi:10.1093/infdis/jiac067. https://doi.org/10.1093/infdis/jiac067
  5. Boukhvalova M, McKay J, Mbaye A, Sanford-Crane H, Blanco JC, Huber A, Herold BC. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model. J Virol 2015;89(19):9825-9840. doi:10.1128/JVI.01387-15. https://doi.org/10.1128/JVI.01387-15
  6. Minaya MA, Korom M, Wang H, Belshe RB, Morrison LA. The Herpevac trial for women: Sequence analysis of glycoproteins from viruses obtained from infected subjects. PLoS One 2017;12(4):e0176687. doi:10.1371/journal.pone.0176687. https://doi.org/10.1371/journal.pone.0176687
  7. Heilingloh CS, Lull C, Kleiser E, Alt M, Schipper L, Witzke O, Trilling M, Eis-Hübinger AM, Dittmer U, Krawczyk A. Herpes Simplex Virus Type 2 Is More Difficult to Neutralize by Antibodies Than Herpes Simplex Virus Type 1. Vaccines 2020;8(3):478. doi:10.3390/vaccines8030478. https://doi.org/10.3390/vaccines8030478
  8. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki R-Y, Slaoui M, Denis M, Vandepapeliere P, Dubin G. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347(21):1652-1661. doi:10.1056/NEJMoa011915. https://doi.org/10.1056/NEJMoa011915
  9. Johnston C, Scheele S, Bachmann L, Boily MC, Chaiyakunapruk N, Deal C, Delany-Moretlwe S, Lee S, Looker K, Marshall C, Mello MB, Ndowa F, Gottlieb S. Vaccine value profile for herpes simplex virus. Vaccine 2024;42(19 Suppl 1):S82-S100. doi:10.1016/j.vaccine.2024.01.044. https://doi.org/10.1016/j.vaccine.2024.01.044
  10. Bai L, Xu J, Zeng L, Zhang L, Zhou F. A review of HSV pathogenesis, vaccine development, and advanced applications. Mol Biomed 2024;5(1):35. doi:10.1186/s43556-024-00199-7. https://doi.org/10.1186/s43556-024-00199-7
  11. Collins-Ogle M, Herold BC. Developments in genital herpes: progress in prevention and treatment. Curr Opin Infect Dis 2026;39(1):61-66. doi:10.1097/QCO.0000000000001177. https://doi.org/10.1097/QCO.0000000000001177